Vol 9: Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.Reportar como inadecuado



 Vol 9: Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.


Vol 9: Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 9: Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.
This article is from International Journal of Chronic Obstructive Pulmonary Disease, volume 9.AbstractPurpose: Fixed-dose combinations of inhaled corticosteroids and long-acting β2-agonists have proven to prevent and reduce chronic obstructive pulmonary disease COPD exacerbations. The aim of this analysis was to explore the clinical consequences and direct health care costs of applying the findings of the PATHOS An Investigation of the Past 10 Years Health Care for Primary Care Patients with Chronic Obstructive Pulmonary Disease study to the Italian context. Patients and methods: Effectiveness data from the PATHOS study, a population-based, retrospective, observational registry study conducted in Sweden, in terms of reduction in COPD and pneumonia-related hospitalizations, were considered, in order to estimate the differences in resource consumption between patients treated with budesonide-formoterol and fluticasone-salmeterol. The base case considers the average dosages of the two drugs reported in the PATHOS study and the actual public price in charges to the Italian National Health Service, while the difference in hospitalization rates reported in the PATHOS study was costed based on Italian real-world data. Results: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide-formoterol versus fluticasone-salmeterol −29.1% and −42%, respectively. In the base case, the treatment of a patient for 1 year with budesonide-formoterol led to a saving of €499.90 €195.10 for drugs, €193.10 for COPD hospitalizations, and €111.70 for pneumonia hospitalizations corresponding to a −27.6% difference compared with fluticasone-salmeterol treatment. Conclusion: Treatment of COPD with budesonide-formoterol compared with fluticasone-salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes.



Autor: Roggeri, Alessandro; Micheletto, Claudio; Roggeri, Daniela Paola

Fuente: https://archive.org/







Documentos relacionados